Monza, Italy · HCM myectomy that addresses abnormal mitral chordae
Research by Yevhenii Kozlov · Co-Founder of BookimedUpdated 8 October 2026Sources linked throughout
At a glance
Monza’s HCM work combines muscle resection with correction of selected abnormal secondary mitral chordae. The purpose is anatomical relief of obstruction while retaining the native valve, with longer follow-up than a purely early feasibility report.
350-patient follow-up
The 2026 publication studies 350 consecutive patients with median follow-up of 5.6 years.
This is observational centre evidence, not a randomized comparison with other myectomy methods. The scientific-director title for Ferrazzi comes from a 2023 brochure; the 2026 paper establishes his research affiliation rather than a personal operating schedule.
Paolo Ferrazzi’s Monza work treats obstructive HCM by removing excess heart muscle and selectively cutting abnormal cords that pull on the mitral valve. The aim is to open the outflow pathway while keeping the patient’s own valve. The published 350-patient study has a median 5.6 years of follow-up.
Monza research affiliation documented in 2026; the scientific-director appointment source is dated 2023.
The 2026 JACC report studied 350 consecutive patients treated at one centre over a five-year operating period. Follow-up was available for 344 patients. At the latest assessment, 271 were in NYHA class I and 65 in class II.
How to interpret this: These are centre-cohort results, not Ferrazzi’s independently audited personal total. This observational study did not compare this technique directly with Cui’s MESM or other European surgeons.
